What is Goserelin?
Goserelin (brand name ZOLADEX) is a synthetic decapeptide agonist of gonadotropin-releasing hormone (GnRH; also called LHRH). It was approved by the FDA on December 29, 1989 and remains a workhorse hormonal therapy for sex-hormone-driven cancers and gynecologic disorders.
Goserelin is delivered as a subcutaneous depot implant (a small biodegradable cylinder injected under the skin of the abdomen) every 28 days for the 1-month formulation or every 12 weeks for the 3-month formulation. The depot delivery eliminates daily injection burden.
Structure and Mechanism
Goserelin is a modified analogue of native GnRH (10 amino acids), with two key modifications:
- D-Ser(tert-butyl) at position 6 — increases receptor affinity and resistance to enzymatic cleavage
- Aza-glycine amide at position 10 — extends half-life
These modifications make goserelin a long-acting GnRH receptor agonist.
The therapeutic mechanism is paradoxical: continuous GnRH receptor activation (rather than the natural pulsatile GnRH release) initially stimulates LH and FSH release (causing a brief "flare") but then produces profound desensitization of pituitary gonadotrophs over 1-2 weeks. The result is suppression of LH and FSH, which suppresses testosterone in men (≥95% reduction to castrate levels) and estradiol in premenopausal women.
This pharmacological castration is the basis of goserelin's therapeutic effects across multiple sex-hormone-driven conditions.
Approved Indications
- Advanced prostate cancer — palliative treatment to suppress testosterone
- Locally confined prostate cancer (Stage B2-C) — neoadjuvant/adjuvant with radiation therapy
- Advanced breast cancer in premenopausal/perimenopausal women — only GnRH agonist FDA-approved for this indication
- Endometriosis — symptom management and lesion regression
- Endometrial thinning — pre-procedure preparation before endometrial ablation surgery
Clinical Evidence
Prostate cancer:
- Equivalent overall survival to surgical orchiectomy in advanced disease
- Reversible vs surgical castration (testosterone recovers after discontinuation in younger men)
- Combined with radiation, improves long-term survival in locally advanced disease
ZEBRA trial (premenopausal breast cancer):
- Goserelin produced equivalent disease-free survival to CMF chemotherapy in node-positive ER+ premenopausal breast cancer
- Established GnRH agonist therapy as a chemotherapy alternative in this population
Approval History
- December 29, 1989 — FDA approval (initial: prostate cancer, then expanded)
- 1995, 1996 — Breast cancer, endometriosis, endometrial thinning indications added
- 3-month depot approved 1996; longer-acting formulations followed
Place in Therapy
Goserelin is one of several GnRH agonists in clinical use (with leuprolide, triptorelin, histrelin, nafarelin, buserelin). Choice between agents typically reflects:
- Formulary access
- Dosing convenience (depot duration)
- Local prescribing patterns
For premenopausal breast cancer, goserelin retains its specific FDA approval and is the standard choice in most US oncology practices.
Safety Profile
Adverse events reflect the on-target hypogonadism:
- Tumor flare — initial testosterone surge can transiently worsen prostate cancer symptoms or cause spinal cord compression in heavy bony disease (mitigated by anti-androgen co-therapy in the first 4 weeks)
- Hot flashes, decreased libido, erectile dysfunction in men
- Hot flashes, vaginal dryness, mood changes in women
- Bone mineral density loss with chronic use (boxed warning for >6 months use in some indications)
- Cardiovascular and metabolic effects with long-term use
Distinction from Triptorelin, Leuprolide, and Histrelin
All four are GnRH agonists with similar receptor pharmacology. Differences lie in:
- Goserelin (Zoladex) — depot SC implant, 1- or 3-month
- Leuprolide (Lupron) — many depot formulations (1, 3, 4, 6 months); also for CPP
- Triptorelin (Trelstar) — IM depot, 1, 3, 6 months
- Histrelin (Supprelin LA) — annual SC implant; primarily pediatric central precocious puberty
The choice is largely formulary/access-driven; clinical efficacy is similar across the class.